INTRODUCTION {#sec1-1}
============

The Wilms' tumor gene (WT1) was originally introduced as a tumor-suppressor gene.\[[@ref1][@ref2]\]

A transcription factor with zinc figure motifs encoded by this gene suppresses the transcription of some growth factor genes including PDGF-A, CSF-1 and IGF-II as well as growth factor receptor gene IGF-1R.\[[@ref3]\]

Its mutation and inactivation was seen in a subset of Wilms' tumor and children who were genetically predisposed to kidney neoplasm.\[[@ref3][@ref4]\] Further research showed that wild-type WT1 has oncogenic properties and its continuous over-expression is related to leukemia\[[@ref5]\] and several kinds of solid malignancies including lung,\[[@ref6]\] colon,\[[@ref7]\] breast\[[@ref8][@ref9]\] and thyroid cancer.\[[@ref10][@ref11]\]

Wild-type WT1 over expression has also been found in astrocytic tumors.\[[@ref1][@ref3][@ref12]\] WT1 expression has been reported in the majority of patients suffering from malignant astrocytoma.\[[@ref13]\] Identification of WT1 protein as a tumor-associated antigen made it an attractive option for immunotherapy against malignancies, particularly brain tumors because it has an important role in regulation of tumorigenesis and it does not express in the normal brain.\[[@ref4][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19]\] In addition, MIB-1 staining index is a marker of tumor cell proliferation and has proven diagnostic value in astrocytic tumors.\[[@ref20][@ref21]\]

This study aimed to evaluate WT1 protein expression levels and its association with cellular proliferation in astrocytic brain tumors by immunohistochemical methods.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design {#sec2-1}
------------

This cross-sectional study was performed at Alzahra Hospital, Isfahan, Iran, on tissue samples obtained from patients who had undergone brain surgery between 2007 and 2010. This study was approved by the ethics committee of Isfahan University of Medical Sciences.

Tissue samples {#sec2-2}
--------------

After evaluation of hematoxylin and eosin (H and E) stained slides, 73 paraffin blocks ((2)) were randomly selected from astrocytic tumor samples of different grades, archived at pathology unit of our center. Samples with unsatisfactory amount of tissue were excluded. Definite diagnosis of different grades of astrocytic brain tumors was made according to World Health Organization (WHO) diagnostic criteria.\[[@ref22]\]

Immunohistochemistry {#sec2-3}
--------------------

### Deparaffinization and antigen retrieval {#sec3-1}

Four micrometer thickness formalin-fixed tissue sections were cut from each paraffin block and placed on poly-L-lysine covered slides. Sections were heated in dry oven at 60°C for 30--45 min, then immersed in xylene, alcohol, and finally citrate buffer (pH»6).

### WT1 staining {#sec3-2}

Sections were incubated with anti-human WT1 antibody (6F-H2, DAKO, U.S.A.; diluted 1:40)((7)) for 1 h, then following solutions were added for specific time orderly: 0.3% H~2~O~2~ solution for 10 min, EnVisionä polymer for 25 min, Diaminobenzidine (DAB) for 5 min and hematoxylin for 2 min. Samples were washed after each step by Phosphate Buffered Saline (PBS).

A Wilms' tumor sample was stained based on the above method and considered as the positive control.

### MIB-1 staining {#sec3-3}

Sections similar to those selected for WT1 staining were recruited for MIB-1 staining, incubated with anti Ki-67 antibody (DAKO, U.S.A.; diluted 1:80)((7)) for 1 h. Other steps were performed on the same serial steps used for WT1 immunohistochemistry.

A lymph node sample was stained according to the above method for positive control.

Sample evaluation {#sec2-4}
-----------------

All specimens were observed under light microscope at high magnification. Only samples in which endothelial cells showed WT1 expression were included the study. WT1 index was determined as the sum of WT1-positive relative frequency score and WT1 staining score.

WT1 staining score was considered as 0 (negative: no staining), 1 (weak: mildly increased staining compared to the normal glial cells), 2 (intermediate: staining at intensity between 1 and 3), and 3 (strong: significantly increased staining in tumor cells compared with normal glial cells) (1) ((3)).

Relative frequency of WT1-positive tumor cells was scored as 0 (0%), 1 (\<25%), 2 (25--75%), and 3 (\>75%).\[[@ref3]\]

Regarding MIB-1 staining index, the number of positively stained tumor cell nuclei in every 1000 tumor cell nuclei was calculated.

Statistical analysis {#sec2-5}
--------------------

Data were analyzed by SPSS 16; spearman correlation test, Kruskal-Wallis test and Mann-Witney U test were applied as they were appropriate. *P*\<0.05 was considered as significant statistical difference.

RESULTS {#sec1-3}
=======

According to the WHO grading system, 4 types of brain astrocytic tumors were found among studied samples including pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma and gliobastoma. Majority of cases were glioblastoma (49.31%). Based on immunohistochemical staining, 71 of 73 (97.3%) studied primary astrocytic tumor samples expressed WT1 protein in the cytoplasm. Only 1 sample with glioblastoma and 1 with pilocytic astrocytoma had no WT1 protein expression. High WT1 index (WT1 index: 6) was found significantly more in gliobastoma samples (87.5%) (*P*\<0.001); also MIB-1 staining index was significantly higher in gliobastoma in comparison with diffuse and pilocytic astrocytoma (*P*\<0.001) \[[Table 1](#T1){ref-type="table"} and Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}\].

###### 

Distribution of various tumor grades and relevant indices
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![Strong WT1 protein expression (a) and high proportion of ki-67 positive nuclei (MIB-1 staining) (b) in a case of glioblastoma multiforme](ABR-2-33-g002){#F1}

![Weak WT1 protein expression (a) and low percentage of ki-67 positive nuclei (MIB-1 staining) (b) in a case of diffuse fibrillary astrocytoma](ABR-2-33-g003){#F2}

Mean rank of WT1 index was significantly different between various grades of astrocytic brain tumor (*P*\<0.001) \[[Table 2](#T2){ref-type="table"}\].

###### 

Comparison of mean rank of WT1 index between different grades of astrocytic brain tumors
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In addition, significant positive correlation was found between MIB-1 staining index and WT1 protein expression index (*r*: 0.64, *P*\<0.001) \[[Figure 3](#F3){ref-type="fig"}\].

![Scatter plot and regression line showing the positive correlation between MIB-1 staining index and WT1 protein expression index](ABR-2-33-g005){#F3}

DISCUSSION {#sec1-4}
==========

The emphasis of previous studies on the role of WT1 protein as a tumor marker led us to conduct this study to evaluate WT1 status in primary brain tumors. This role was confirmed for astrocytic tumors; present study showed that similar to the mentioned kinds of malignancy, majority of astrocytic brain tumors also express WT1 protein. It was also found that high-grade tumors are accompanied with higher WT1 protein expression. These findings are confirmed by the study of *T. Hashiba et al*. in which high WT1 protein expression is considered to be due to probable involvement of WT1 gene in proliferation or transformation of astrocytic tumors.\[[@ref1]\] Another study, which reported a diagnostic value for WT1 in neuroepithelial tumors,\[[@ref23]\] also approved the positive correlation between WT1 protein expression and tumor grade. As well, WT1 was suggested to have a role in tumorigenesis and progression of brain tumors.\[[@ref23]\]

But is WT1 a tumor-specific marker in brain neoplasm as well as other mentioned sorts of cancer? Yes! Another study by Schittenhelm *et al*., which compared normal astrocytes with neoplastic astrocytes, found that in contrast to normal and reactive astrocytes, neoplastic cells express WT1 protein frequently.\[[@ref24]\]

In contrast, a recent study found WT1 not to be a reliable marker for differentiation of reactive from neoplastic astrocytes. However, this different finding is attributed to different tissue fixation and immunohistochemistry methodology.\[[@ref25]\]

Proliferative activity is known as a reliable marker to assess tumor biology and has established power in the diagnosis of astrocytic tumors.\[[@ref20][@ref21]\] MIB-1 is a marker commonly used to denote proliferative activity. We found that along with the progression of tumor grade, MIB-1 staining index demonstrates a continuous increase, which verifies higher proliferative activity in high-grade tumors.\[[@ref1]\] Previous studies support this finding where MIB-1 is reported to be correlated with tumor grade as well as with mitotic activity.\[[@ref1][@ref26][@ref27]\] Low MIB-1 staining index has been considered to be associated with slower tumor growth.\[[@ref28]\]

Based on values we have found, MIB-1 staining index can be used to differentiate glioblastoma from pilocytic and diffuse astrocytoma more reliably.

In spite of higher WT1 protein expression and MIB-1 staining index in high-grade tumors, WT1 index was surprisingly significantly lower in diffuse astrocytoma (grade 2) than pilocytic type (grade 1); Such a finding has been reported in previous studies as well and could be considered as one of the several unclear issues related to the role of WT1 gene in astrocytes, which needs further specific investigations to clarify.\[[@ref1]\]

In addition, the significant positive correlation between WT1 protein expression and MIB-1 staining index implies that WT1 protein expression might be related to both tumor cell proliferation and tumor grade. Albeit, this correlation has been attributed to higher WT1 protein expression in areas of high cell proliferation,\[[@ref1]\] but since we did not observe any specific pattern in the expression of WT1 protein, it could be inferred that higher WT1 protein expression is not necessarily confined to the high proliferation areas. Therefore, this correlation might be more complex than a direct correlation limited to specific sites and could be related to a common underlying condition, which regulates both of these indices; further studies are needed to shed light on the basis of this correlation.

CONCLUSION {#sec1-5}
==========

In summary, we can conclude that proven roles of WT1 in malignancies could be attributable to brain astrocytic tumors; WT1 can be used as a marker of malignant cell proliferation and invasion as well as a diagnostic tool to differentiate normal astrocytes from neoplastic cells. Moreover, over-expression of WT1 in astrocytic brain tumors, especially high-grade types, suggests that this kind of malignancies could be a suitable target for cancer immunotherapy.
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